Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead increases Q2 revenue 13% and pumps up HCV R&D

This article was originally published in Scrip

Executive Summary

Gilead Sciences' reported second quarter 2012 revenue that beat analyst expectations on 26 July and said the company will initiate a Phase III clinical trial before the end of this year to test one of its hepatitis C virus (HCV) therapies in combination with another of its closely-watched HCV candidates before the end of the year.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC018279

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel